Invitae Corporation (NVTA)

Market Cap	178.74M
Revenue (ttm)	493.88M
Net Income (ttm)	-799.67M
Shares Out	270.45M
EPS (ttm)	-3.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,514,073
Open	0.662
Previous Close	0.670
Day's Range	0.632 - 0.685
52-Week Range	0.632 - 3.775
Beta	1.70
Analysts	Sell
Price Target	1.50 (+126.96%)
Earnings Date	Nov 7, 2023

About NVTA

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services. It serves patients, healthcare providers, biopharma companies, and other partners. The company was formerly known as Locus Development, Inc. and changed its name to Invit...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Feb 12, 2015
• Employees: 1,700
• Stock Exchange: NYSE
• Ticker Symbol: NVTA

Financial Performance

In 2022, Invitae's revenue was $516.30 million, an increase of 12.13% compared to the previous year's $460.45 million. Losses were -$3.11 billion, 719.6% more than in 2021.

Analyst Forecast

According to 4 analysts, the average rating for NVTA stock is "Sell." The 12-month stock price forecast is $1.5, which is an increase of 126.96% from the latest price.

Price Target

$1.5

(126.96% upside)

Analyst Consensus: Sell